- Home
- IMA vs GDL Comparison
IMA vs GDL Comparison
Compare IMA & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMA | GDL |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.2M | 94.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IMA | GDL |
|---|---|---|
| Price | $6.49 | $8.47 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 50.1K | 11.2K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.02% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.19 | $7.65 |
| 52 Week High | $18.00 | $8.13 |
Technical Indicators
Market Signals| Indicator | IMA | GDL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 45.72 |
| Support Level | N/A | $8.41 |
| Resistance Level | N/A | $8.52 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 32.35 |
Price Performance
Historical ComparisonAbout IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.